United Therapeutics financials
$481.47−0.84%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $783.3M | $781.5M | $790.2M | $799.5M | $798.6M | $794.4M | $735.9M | $748.9M | $714.9M | $677.7M | $614.7M | $609.4M |
| Gross profit | $683.8M | $648.1M | $686.8M | $698.6M | $711.0M | $701.9M | $660.0M | $665.8M | $637.1M | $604.8M | $543.7M | $539.3M |
| Gross margin | 87.3% | 82.9% | 86.9% | 87.4% | 89.0% | 88.4% | 89.7% | 88.9% | 89.1% | 89.2% | 88.4% | 88.5% |
| Operating income | $330.8M | $325.8M | $356.7M | $388.5M | $364.5M | $382.8M | $357.7M | $343.1M | $319.9M | $356.3M | $260.1M | $327.0M |
| Net income | $333.0M | $274.9M | $364.3M | $338.7M | $309.5M | $322.2M | $301.3M | $309.1M | $278.1M | $306.6M | $217.1M | $267.6M |
| Net margin | 42.5% | 35.2% | 46.1% | 42.4% | 38.8% | 40.6% | 40.9% | 41.3% | 38.9% | 45.2% | 35.3% | 43.9% |
| Diluted EPS | $7.27 | $5.82 | $7.69 | $7.16 | $6.41 | $6.63 | $6.23 | $6.39 | $5.85 | $6.17 | $4.34 | $5.38 |
| EBITDA | $355.0M | $348.4M | $379.5M | $410.4M | $385.6M | $402.6M | $377.4M | $362.2M | $338.6M | $371.3M | $260.1M | $340.3M |
| Operating cash flow | $313.6M | $463.3M | $346.2M | $562.1M | $191.7M | $461.2M | $341.2M | $377.2M | $232.2M | $376.5M | $150.7M | $346.2M |
| Free cash flow | $205.6M | $362.5M | $173.3M | $351.6M | $129.5M | $386.3M | $254.5M | $300.7M | $187.1M | $338.3M | $72.0M | $280.5M |
| Diluted shares | 45.8M | 47.2M | 47.4M | 47.3M | 48.3M | 48.6M | 48.4M | 48.4M | 47.5M | 49.7M | 50.0M | 49.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.80B | $1.28B | $1.56B | $1.34B | $1.59B | $1.90B |
| Short-term investments | $859.1M | $874.0M | $1.36B | $1.43B | $1.46B | $1.42B |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $200.0M |
| Total assets | $7.22B | $6.71B | $7.88B | $7.35B | $7.91B | $7.74B |
| Total liabilities | $819.8M | $813.1M | $783.8M | $760.9M | $734.4M | $936.7M |
| Shareholders' equity | $6.40B | $5.90B | $7.10B | $6.59B | $7.17B | $6.81B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology